Follow
Massimo Fantini
Massimo Fantini
Director Research and Development, Precision Biologics Inc.
Verified email at nih.gov
Title
Cited by
Cited by
Year
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
B Boyerinas, C Jochems, M Fantini, CR Heery, JL Gulley, KY Tsang, ...
Cancer immunology research 3 (10), 1148-1157, 2015
5712015
In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: Perspectives on cancer treatment
M Fantini, M Benvenuto, L Masuelli, GV Frajese, I Tresoldi, A Modesti, ...
International journal of molecular sciences 16 (5), 9236-9282, 2015
3722015
Dietary flavonoids: molecular mechanisms of action as anti-inflammatory agents
L Marzocchella, M Fantini, M Benvenuto, L Masuelli, I Tresoldi, A Modesti, ...
Recent patents on inflammation & allergy drug discovery 5 (3), 200-220, 2011
1842011
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
C Jochems, JW Hodge, M Fantini, R Fujii, YM Morillon II, JW Greiner, ...
Oncotarget 7 (52), 86359-86373, 2016
1692016
Sarcopenia and fragility fractures: molecular and clinical evidence of the bone-muscle interaction
U Tarantino, E Piccirilli, M Fantini, J Baldi, E Gasbarra, R Bei
J Bone Joint Surg Am 97 (5), 429-437, 2015
1562015
In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
M Benvenuto, L Masuelli, E De Smaele, M Fantini, R Mattera, D Cucchi, ...
Oncotarget 7 (8), 9250-9270, 2016
1192016
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
C Jochems, M Fantini, RI Fernando, AR Kwilas, RN Donahue, LM Lepone, ...
Oncotarget, 2016
1162016
Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas
L Masuelli, E Di Stefano, M Fantini, R Mattera, M Benvenuto, ...
Oncotarget 5 (21), 10745-62, 2014
1092014
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
RN Donahue, LM Lepone, I Grenga, C Jochems, M Fantini, RA Madan, ...
Journal for immunotherapy of cancer 5 (1), 1-16, 2017
912017
Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
L Masuelli, M Benvenuto, M Fantini, L Marzocchella, P Sacchetti, ...
Journal of biological regulators and homeostatic agents 27 (1), 105-119, 2013
762013
Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant …
L Masuelli, M Benvenuto, E Di Stefano, R Mattera, M Fantini, G De Feudis, ...
Oncotarget 8 (21), 34405, 2017
732017
Biological effects of in vitro THz radiation exposure in human foetal fibroblasts
A De Amicis, S De Sanctis, S Di Cristofaro, V Franchini, F Lista, ...
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 793, 150-160, 2015
732015
Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and …
L Masuelli, F Pantanella, G La Regina, M Benvenuto, M Fantini, R Mattera, ...
Tumor Biology 37 (3), 3705-3717, 2016
712016
Co-circulation of dengue and chikungunya viruses, Al Hudaydah, Yemen, 2012
G Rezza, G El-Sawaf, G Faggioni, F Vescio, R Al Ameri, R De Santis, ...
Emerging infectious diseases 20 (8), 1351, 2014
672014
Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials
M Turriziani, M Fantini, M Benvenuto, V Izzi, L Masuelli, P Sacchetti, ...
Recent patents on anti-cancer drug discovery 7 (3), 265-296, 2012
672012
Tendon’s ultrastructure
I Tresoldi, F Oliva, M Benvenuto, M Fantini, L Masuelli, R Bei, A Modesti
Muscles, ligaments and tendons journal 3 (1), 2, 2013
652013
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
GSR Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR ...
Oncoimmunology 7 (11), e1466018, 2018
632018
Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis
L Masuelli, L Marzocchella, C Focaccetti, I Tresoldi, C Palumbo, V Izzi, ...
Front Biosci 17 (1), 498-508, 2012
502012
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti‐PD‐L1 antibody
C Jochems, JW Hodge, M Fantini, KY Tsang, AJ Vandeveer, JL Gulley, ...
International journal of cancer 141 (3), 583-593, 2017
492017
Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro
GV Frajese, M Benvenuto, M Fantini, E Ambrosin, P Sacchetti, L Masuelli, ...
Oncology Letters 11 (6), 4224-4234, 2016
402016
The system can't perform the operation now. Try again later.
Articles 1–20